BOUNDLESS: AN ACTIVE-CONTROLLED, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY TRIAL OF CONTINUOUS SUBCUTANEOUS INFUSION OF LEVODOPA/CARBIDOPA WITH ND0612 IN PATIENTS WITH PARKINSON'S DISEASE

被引：0
|
作者：
Rascol, O. [1 ,2 ]
Poewe, W. [3 ]
Stocchi, F. [4 ]
Yardeni, T. [5 ]
Barak, S. Leibman [5 ]
Adar, L. [5 ]
Rosenfeld, O. [5 ]
Olanow, C. W. [6 ]
机构：
[1] Univ Toulouse, CHU Toulouse, Toulouse, France
[2] INSERM, Toulouse, France
[3] Med Univ Innsbruck, Innsbruck, Austria
[4] IRCCS San Raffaele Pisana, Inst Neurol, Rome, Italy
[5] NeuroDerm Ltd, Rehovot, Israel
[6] Clintrex, Sarasota, FL USA
来源：
PARKINSONISM & RELATED DISORDERS | 2020年 / 79卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
A 186
引用
收藏
页码：E53 / E53
页数：1
相关论文
共 50 条
  • [21] Double-Blind Trial of Levodopa/Carbidopa/Entacapone Versus Levodopa/Carbidopa in Early Parkinson's Disease
    Hauser, Robert A.
    Panisset, Michel
    Abbruzzese, Giovanni
    Mancione, Linda
    Dronamraju, Nalina
    Kakarieka, Algirdas
    MOVEMENT DISORDERS, 2009, 24 (04) : 541 - 550
  • [22] for the LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study (vol 13, pg 141, 2014)
    Olen, C. W.
    Kieburtz, K.
    Odin, P.
    LANCET NEUROLOGY, 2014, 13 (03): : 240 - 240
  • [23] Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial
    Soileau, Michael J.
    Aldred, Jason
    Budur, Kumar
    Fisseha, Nahome
    Fung, Victor Sc
    Jeong, Anna
    Kimber, Thomas E.
    Klos, Kevin
    Litvan, Irene
    O'Neill, Daniel
    Robieson, Weining Z.
    Spindler, Meredith A.
    Standaert, David G.
    Talapala, Saritha
    Vaou, Eleni Okeanis
    Zheng, Hui
    Facheris, Maurizio F.
    Hauser, Robert A.
    LANCET NEUROLOGY, 2022, 21 (12): : 1099 - 1109
  • [24] VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis
    Schreiber, Stefan
    Peyrin-Biroulet, Laurent
    Loftus, Edward V., Jr.
    Danese, Silvio
    Colombel, Jean-Frederic
    Abhyankar, Brihad
    Chen, Jingjing
    Rogers, Raquel
    Lirio, Richard A.
    Bornstein, Jeffrey D.
    Sands, Bruce E.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S612 - S613
  • [25] Efficacy and Safety of Foslevodopa/Foscarbidopa Versus Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients: Design of a Phase 3, Randomized, Double-Blind, Double-Dummy, Active Controlled 12-Week Trial
    Facheris, Maurizio
    Robieson, Weining
    Fisseha, Nahome
    Standaert, David
    NEUROLOGY, 2021, 96 (15)
  • [26] Efficacy and safety of foslevodopa/foscarbidopa versus oral carbidopa/levodopa in advanced Parkinson's disease patients: Design of a phase 3, randomized, double-blind, double-dummy, active controlled 12-week trial
    Facheris, Maurizio
    Robieson, Weining
    Fisseha, Nahome
    Standaert, David
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 331 - 331
  • [27] Pharmacokinetic and safety characterisation of carbidopa/levodopa subcutaneous infusion (ND0612): Phase I studies in healthy volunteers and patients with fluctuating Parkinson's disease
    Lewitt, P.
    Caraco, Y.
    Adar, L.
    Oren, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 514 - 514
  • [28] Subgroup Analyses of a Phase 3 Randomized Study of Levodopa/Carbidopa Infusion (ND0612) for Parkinson's Patients
    Poewe, W.
    Espay, A.
    Lopes, N.
    Ferreira, J.
    MOVEMENT DISORDERS, 2024, 39 : S306 - S306
  • [29] CONTINUOUS SUBCUTANEOUS LEVODOPA/CARBIDOPA INFUSION WITH ND0612 FOR PARKINSON'S DISEASE: THREE-YEAR DATA FROM THE OPEN-LABEL BEYOND STUDY
    Stocchi, F.
    Poewe, W.
    Ellenbogen, A.
    Adar, L.
    Salin, L.
    Case, R.
    Yardeni, T.
    Giladi, N.
    PARKINSONISM & RELATED DISORDERS, 2024, 122
  • [30] Comparison of Orally Dissolving Carbidopa/Levodopa (Parcopa) to Conventional Oral Carbidopa/Levodopa: A Single-Dose, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover Trial
    Ondo, William G.
    Shinawi, Lina
    Moore, Steven
    MOVEMENT DISORDERS, 2010, 25 (16) : 2724 - 2727
12345